NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports

30 Dec 2024
MELBOURNE, Australia and BRUSSELS, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and the Brussels-based Oncidium foundation today announce that results for the NOBLE Registry of TLX599-CDx ( 99m Tc-iPSMA) have been published in the
Read More

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

29 Dec 2024
MELBOURNE, Australia and INDIANAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for
Read More

Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete

19 Dec 2024
MELBOURNE, Australia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has completed the installation of two new cyclotrons at Telix Manufacturing Solutions (TMS) in Brussels South, Belgium, facilitating the
Read More

Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

18 Nov 2024

MELBOURNE, Australia , Nov. 19, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix , the Company) today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in

Read More

Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology

13 Nov 2024

Telix today announces that it has entered into a technology collaboration and licence agreement with Berlin-based Eckert & Ziegler SE (EZAG) for the use of EZAG’s cyclotron-based systems to produce the alpha-emitting isotope, actinium-225 ( 225 Ac). This provides Telix with both an additional

Read More

Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals

04 Nov 2024

Telix today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialised diagnostic radiopharmaceuticals [1]  for Medicare Fee for Service patients in the hospital outpatient setting, beyond the transitional

Read More

Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®

30 Oct 2024

Telix today announces a partnership with California-based Subtle Medical, Inc. (Subtle Medical) for artificial intelligence (AI)-powered positron emission tomography (PET) imaging with Telix’s commercial PSMA-PET [1]  product, Illuccix® ( 68 Ga-PSMA-11). Subtle Medical’s SubtlePET™ is a U.S.

Read More

FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent

24 Oct 2024

Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara® [1] ), an agent for the imaging of glioma. The application has been granted priority review and designated a PDUFA [2]  goal date of 26 April

Read More